Amantadine, Fatigue, and Multiple Sclerosis
1988; American Medical Association; Volume: 45; Issue: 10 Linguagem: Inglês
10.1001/archneur.1988.00520340058012
ISSN1538-3687
AutoresGary A. Rosenberg, Otto Appenzeller,
Tópico(s)Healthcare and Venom Research
ResumoIn a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six. Administration of the drug was associated with significantly higher levels of beta-endorphin-beta-lipotropin and responders had significantly higher levels than nonresponders. Lactate levels were significantly higher and pyruvate levels lower in nonresponders. Amantadine given for fatigue to patients with multiple sclerosis is associated with measurable changes in levels of metabolites and peptides in the circulation.
Referência(s)